FDA's August 2026 PDUFA Wave: Five Landmark Decisions Regulatory Affairs Professionals Need to Know

The FDA PDUFA dates for August 2026 mark one of the busiest single-month regulatory windows of the year, with five separate Prescription Drug User Fee Act (PDUFA) decisions due between 5 and 28 August. The decisions affect a new mRNA influenza vaccine, an oral multiple myeloma therapy, a single-tablet HIV regimen, a radiopharmaceutical for neuroendocrine tumours, and a first-in-class treatment for an ultra-rare bone disorder. Sponsors include Moderna, Bristol Myers Squibb, Gilead Sciences, ITM Isotope Technologies Munich and Regeneron. Regulatory affairs professionals, sponsors and investors are watching closely because the outcomes will shape competitive positioning, patient access and post-approval workstreams across four therapeutic areas simultaneously.

Contents

1. At a Glance

2. Background: Why the August 2026 PDUFA Wave Matters

3. mFLUSIVA (mRNA-1010): The First mRNA Flu Vaccine Reaches Its Decision Point

4. Iberdomide: Bristol Myers Squibb's CELMoD Bid in Multiple Myeloma

5. Bictegravir/Lenacapavir and 177Lu-Edotreotide: Two Contrasting Priority Reviews

6. Garetosmab: A First-in-Class Therapy for Fibrodysplasia Ossificans Progressiva

7. Deepen Your Knowledge: Regulatory Affairs Training on This Topic

8. Practical Implications for Regulatory Affairs Professionals

9. Key Takeaways

10. Take the Next Step in Your Regulatory Affairs Career

11. Frequently Asked Questions

12. Further Reading and Reference Sources

At a Glance

- Five FDA PDUFA (Prescription Drug User Fee Act) decisions fall within a single 23-day window, from 5 August to 28 August 2026.

- mFLUSIVA (mRNA-1010) from Moderna received full approval on 5 August 2026 for adults 50–64 and accelerated approval for adults 65+, becoming the first licensed mRNA seasonal influenza vaccine in the US.

- Iberdomide, Bristol Myers Squibb's CELMoD (cereblon E3 ligase modulator) agent for relapsed/refractory multiple myeloma (RRMM), has a PDUFA date of 17 August 2026.

- Bictegravir/lenacapavir (BIC/LEN), Gilead Sciences' single-tablet HIV regimen, is due a decision by 27 August 2026 under Priority Review.

- 177Lu-edotreotide (ITM-11), ITM Isotope Technologies Munich's radiotherapeutic for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), has a PDUFA date of 28 August 2026.

- Garetosmab, Regeneron's Activin A-targeting antibody for the ultra-rare disorder fibrodysplasia ossificans progressiva (FOP), carries an August 2026 decision window, though the FDA has not published an exact calendar day.

- Four separate designations — Breakthrough Therapy, Fast Track, Orphan Drug and Priority Review — apply across these five products, illustrating the FDA's expedited pathway toolkit in active use.

Background: Why the August 2026 PDUFA Wave Matters

The Prescription Drug User Fee Act (PDUFA) sets statutory review-goal dates that discipline the FDA's timeline for acting on New Drug Applications (NDAs) and Biologics License Applications (BLAs). When several PDUFA dates cluster in the same month, as they have in August 2026, it is rarely coincidental — it reflects the pace of NDA/BLA submissions roughly ten to twelve months earlier, layered with Priority Review designations that compress the standard ten-month review clock to six months. This year's cluster is notable not just for its density but for its therapeutic breadth: a preventive vaccine, an oncology CELMoD, an antiretroviral combination, a radiopharmaceutical, and a rare-disease biologic are all reaching decision points within three weeks of each other, each carrying distinct regulatory and commercial stakes for its sponsor.

Interested in building a career in regulatory affairs and working with frameworks like the FDA's Prescription Drug User Fee Act, Priority Review and Breakthrough Therapy pathways? The United States Regulatory Affairs Course at Entry to Regulatory covers the FDA regulatory framework, IND and NDA processes, post-approval changes and FDA regulatory strategy, giving you the practical knowledge, real work experience and job search support to break into or advance within regulatory affairs. - 50+ CPD-accredited hours of expert-led training - Up to 3 months of real regulatory work experience - Mentoring and job search support until you are employed - Covers EU, UK and US pharmaceutical regulations - Taught by a regulatory affairs expert with 10+ years at MHRA, GSK, MSD and Bayer - Study online, part-time, just 6 hours per week View the course and start with a free introductory webinar: https://pages.entrytoregulatory.com/courses/

This month's cluster also arrives against a backdrop of continued FDA use of expedited pathways to bring innovative therapies to patients faster without lowering the evidentiary bar. Several of this month's applications carry more than one expedited designation stacked together — for example, iberdomide holds both Breakthrough Therapy Designation and Priority Review, while garetosmab carries Fast Track, Orphan Drug Designation and Priority Review simultaneously. This layering reflects a broader regulatory history stretching back to the 1992 introduction of PDUFA itself, and the subsequent addition of accelerated approval, breakthrough therapy, and orphan drug frameworks designed to address serious conditions and unmet medical need. Understanding how these designations interact — and how they shape a sponsor's regulatory strategy and submission timeline — is a core component of the Entry to Regulatory regulatory affairs training programme, which covers FDA expedited pathways as part of its practical curriculum for EU, UK and US regulations — see the full course details at https://pages.entrytoregulatory.com/courses/

mFLUSIVA (mRNA-1010): The First mRNA Flu Vaccine Reaches Its Decision Point

On 5 August 2026, Moderna, Inc. announced that its influenza vaccine mFLUSIVA (mRNA-1010) received FDA approval for adults aged 50 and older — full approval for the 50–64 age group and accelerated approval for adults 65 and over, based on immunogenicity data. This is the first mRNA-based seasonal influenza vaccine licensed in the United States and represents Moderna's fourth FDA-approved product overall.

The approval followed an unusual regulatory path. The FDA initially issued a refusal-to-file (RTF) over concerns about the adequacy of the trial design and its use of a standard-dose comparator in older adults. Moderna contested the decision and proposed a revised regulatory approach, after which the FDA reversed course and accepted the application, with a PDUFA goal date of 5 August 2026. On 18 June 2026, the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 in favour, concluding that benefits outweighed risks.

> "The [Phase 3] trial demonstrated a 26.6% relative vaccine efficacy against influenza-like illness compared with a standard-dose vaccine."

> — Summary of Phase 3 trial findings presented to the FDA Advisory Committee, 18 June 2026

Key facts, verified across multiple sources:

1. The pivotal Phase 3 trial enrolled 40,805 participants.

2. Post-marketing study requirements apply to the accelerated approval component for the 65+ population.

3. Moderna is pursuing parallel regulatory submissions in the EU, Canada and Australia.

4. The vaccine is targeted for availability ahead of the 2026–2027 respiratory season.

Iberdomide: Bristol Myers Squibb's CELMoD Bid in Multiple Myeloma

Bristol Myers Squibb submitted its NDA for iberdomide, a cereblon E3 ligase modulator (CELMoD) agent, for patients with relapsed or refractory multiple myeloma (RRMM), in combination with daratumumab (Darzalex) and dexamethasone. The FDA accepted the application on 17 February 2026, granting both Breakthrough Therapy Designation and Priority Review, with a PDUFA target action date of 17 August 2026. If approved, iberdomide would become the first approved CELMoD agent in its class.

The application is supported by the Phase 3 EXCALIBER-RRMM study, which evaluates efficacy using minimal residual disease (MRD) negativity rates and progression-free survival (PFS) as key endpoints — both increasingly important surrogate markers in modern haematology-oncology submissions. The review is also proceeding under the FDA's Project Orbis initiative, which enables simultaneous, collaborative review by multiple international regulators alongside the FDA.

Regulatory professionals looking to deepen their understanding of oncology submission strategy, expedited designations and MRD-based endpoints will find relevant practical training in the Entry to Regulatory course, which includes hands-on assignments covering NDA and BLA submission structures as part of its US regulatory curriculum. Full details at https://pages.entrytoregulatory.com/courses/

Bictegravir/Lenacapavir and 177Lu-Edotreotide: Two Contrasting Priority Reviews

Gilead Sciences is awaiting a decision on bictegravir/lenacapavir (BIC/LEN), a once-daily, single-tablet HIV regimen for virologically suppressed adults, combining the integrase inhibitor bictegravir with the first-in-class capsid inhibitor lenacapavir. The FDA accepted the NDA under Priority Review (announced 29 April 2026), with a PDUFA date of 27 August 2026. The application is supported by the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, and if approved, BIC/LEN would be the smallest single-tablet HIV regimen available.

Separately, ITM Isotope Technologies Munich SE is awaiting a decision on 177Lu-edotreotide (ITM-11), a targeted radiotherapeutic for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), with a PDUFA goal date of 28 August 2026. The application rests on the Phase 3 COMPETE trial, comparing 177Lu-edotreotide against everolimus. 

Trial Metric	177Lu-Edotreotide	Everolimus (comparator)
Median progression-free survival	23.9 months	14.1 months
Overall response rate	21.9%	4.2%
Treatment-emergent adverse events	82.5%	97.0%

Source: COMPETE trial data as reported by CancerNetwork and ITM Isotope Technologies Munich SE.

These two applications illustrate contrasting regulatory profiles within the same PDUFA week: one a lifecycle-extension combination in a well-established therapeutic class (HIV), the other a novel radiopharmaceutical mechanism in a rare tumour type — both moving through Priority Review but for very different strategic reasons.

Garetosmab: A First-in-Class Therapy for Fibrodysplasia Ossificans Progressiva

Regeneron Pharmaceuticals has a Biologics License Application (BLA) under Priority Review for garetosmab, a monoclonal antibody targeting Activin A, intended to treat fibrodysplasia ossificans progressiva (FOP) — an ultra-rare genetic disorder affecting an estimated 900 people globally, causing progressive and irreversible heterotopic (abnormal) bone formation. The product also holds Fast Track and Orphan Drug Designation. Multiple sources confirm an FDA decision expected in August 2026, though the exact calendar day has not been published in the sources reviewed for this article and should be treated as unverified pending official FDA confirmation.

The BLA is supported by the Phase 3 OPTIMA trial, which met its primary endpoint with a 90–94% reduction in new heterotopic bone lesions at 56 weeks and more than a 99% reduction in lesion volume. If approved, garetosmab would be the first treatment shown to meaningfully reduce new bone lesion formation in FOP patients, addressing a condition with no currently approved disease-modifying therapy.

Deepen Your Knowledge: Regulatory Affairs Training on This Topic

Following a PDUFA wave like this one requires more than reading press releases — it requires understanding how NDAs and BLAs move through FDA review, how designations like Priority Review, Breakthrough Therapy and Orphan Drug interact, and how sponsors build regulatory strategy around trial endpoints such as MRD negativity or progression-free survival. These are precisely the skills that separate a regulatory affairs professional who can read a PDUFA calendar from one who can help build a submission strategy around it.

The Entry to Regulatory curriculum directly addresses these areas through its US-focused modules, covering the FDA regulatory framework, IND and NDA processes, post-approval changes and supplements, and how to navigate FDA guidance documents. Alongside this, the broader curriculum covers marketing authorisation submissions, variations, clinical trial applications and CMC regulatory affairs, giving learners a rounded view of how a product moves from clinical development through to post-approval lifecycle management across US, EU and UK frameworks.

This training is particularly valuable for life science graduates seeking entry-level regulatory affairs roles, pharmacists and healthcare professionals looking to move into office-based industry careers, and scientists or QC/QA specialists wanting to pivot into strategic regulatory positions. Because every product in this month's PDUFA wave — from a vaccine to a rare disease biologic — moves through the same underlying FDA framework, understanding that framework has direct, transferable value regardless of therapeutic area specialism.

TRAINING SPOTLIGHT BOX: Course: Introduction to Regulatory Affairs Course Provider: Entry to Regulatory Relevant to this topic: FDA regulatory framework and review pathways, IND and NDA/BLA processes, Priority Review and expedited designations (Breakthrough Therapy, Fast Track, Orphan Drug), post-approval changes and supplements, FDA guidance document navigation Format: Online, part-time | 6 hours per week | 3 months Includes: Up to 3 months real work experience, job mentoring, CV review, mock interviews, industry-recognised certificate Suitable for: Life science graduates, pharmacy professionals, career changers, scientists seeking regulatory transition Start here: https://pages.entrytoregulatory.com/courses/

Practical Implications for Regulatory Affairs Professionals

The August 2026 PDUFA cluster raises practical questions for sponsors, regulatory affairs teams and market access professionals monitoring these programmes. The table below summarises the key questions and how the regulatory picture has shifted this month.

Key Question	Previous Situation	What Changes Now
Is there a licensed mRNA seasonal flu vaccine in the US?	No mRNA-based flu vaccine had been approved in the US	mFLUSIVA (mRNA-1010) is approved as of 5 August 2026, creating a new competitive category ahead of the 2026–2027 respiratory season
What designations apply to iberdomide's review?	NDA accepted with Breakthrough Therapy and Priority Review status	PDUFA date of 17 August 2026 will confirm whether the first CELMoD agent reaches the US multiple myeloma market
How does BIC/LEN compare with existing HIV regimens?	Existing single-tablet regimens require larger pill burdens or more frequent dosing adjustments	If approved by 27 August 2026, BIC/LEN would be marketed as the smallest single-tablet HIV regimen available
Is there an approved treatment for GEP-NETs beyond everolimus?	Everolimus has been a standard comparator/treatment option	A 28 August 2026 approval of 177Lu-edotreotide would introduce a targeted radiotherapeutic alternative with stronger PFS/ORR data
Does an approved therapy exist for FOP?	No disease-modifying treatment for FOP is approved in the US	Garetosmab's BLA, if approved in August 2026, would be the first therapy shown to meaningfully reduce new bone lesion formation
How many expedited designations are stacked across this month's applications?	Designations were reviewed and tracked individually per product	Four distinct designations (Priority Review, Breakthrough Therapy, Fast Track, Orphan Drug) apply across the five applications, useful as a live case study in expedited pathway strategy
What should sponsors with pending applications this month prepare for?	Standard post-decision communication planning	Regulatory, medical affairs and market access teams should have day-one communication, launch and post-marketing commitment plans ready given the density of decisions in a single month

Key Takeaways

1. Track the full PDUFA calendar, not just headline dates. With five decisions in one month, regulatory teams monitoring competitor or partner pipelines should build a rolling August 2026 tracker rather than relying on single-product alerts.

2. Review post-marketing commitments closely for accelerated approvals. mFLUSIVA's accelerated approval pathway for the 65+ population carries confirmatory study obligations that regulatory affairs teams supporting similar vaccine or biologic submissions should study as a template.

3. Monitor Project Orbis implications for iberdomide. Sponsors pursuing simultaneous international review should examine how Project Orbis participation affected iberdomide's review timeline and prepare comparable submission packages if pursuing multi-market strategies.

4. Benchmark endpoint selection for oncology and rare disease programmes. The use of MRD negativity in iberdomide's review and lesion volume reduction in garetosmab's review illustrate how surrogate and novel endpoints are shaping modern FDA submissions.

5. Prepare launch-readiness plans ahead of confirmed decision dates. Given the compressed timeline between now and 28 August 2026, regulatory affairs, market access and medical affairs functions should align on launch sequencing now rather than waiting for formal approval letters.

6. Watch for the exact garetosmab PDUFA date. As the specific day has not been publicly confirmed in available sources, professionals tracking this decision should monitor Regeneron's investor communications directly for the confirmed date.

7. Use this cluster as a live case study in expedited pathways. Professionals building regulatory strategy skills should map each of the five products against the designations they hold (Priority Review, Breakthrough Therapy, Fast Track, Orphan Drug) to understand how these tools are combined in practice.

Take the Next Step in Your Regulatory Affairs Career

Following a month like this one — five FDA decisions spanning vaccines, oncology, infectious disease and rare disease — illustrates exactly why regulatory affairs is such a dynamic and intellectually demanding career. Understanding how the FDA's review clock, expedited designations and submission types work together is a core skill for regulatory affairs professionals at every level, from those preparing their first CV to experienced professionals leading global submission strategy.

If this topic has sparked your interest in how FDA decisions like these are shaped behind the scenes, the Entry to Regulatory course is a practical next step, whether you are completely new to the field or looking to specialise further in US regulatory affairs. A free introductory webinar is available as a low-commitment way to learn more about the profession and how training and real work experience can support your transition.

Explore the full course details and register for a free introductory webinar at Entry to Regulatory: https://pages.entrytoregulatory.com/courses/

Frequently Asked Questions

What is a PDUFA date?

 

A PDUFA date is the FDA's statutory review-goal date for acting on a New Drug Application (NDA) or Biologics License Application (BLA), set under the Prescription Drug User Fee Act. Standard review typically allows ten months from acceptance, while Priority Review compresses this to six months.

Which five drugs have FDA decisions due in August 2026?

The five products are mFLUSIVA (mRNA-1010) from Moderna, iberdomide from Bristol Myers Squibb, bictegravir/lenacapavir from Gilead Sciences, 177Lu-edotreotide (ITM-11) from ITM Isotope Technologies Munich, and garetosmab from Regeneron. Their PDUFA dates fall between 5 and 28 August 2026.

Has mFLUSIVA already been approved?

Yes. mFLUSIVA (mRNA-1010) received FDA approval on 5 August 2026 — full approval for adults aged 50–64 and accelerated approval for adults 65 and older, based on immunogenicity data, with confirmatory post-marketing studies required.

What is the difference between an NDA and a BLA?

A New Drug Application (NDA) is submitted for small-molecule drugs, while a Biologics License Application (BLA) is submitted for biologic products such as monoclonal antibodies and vaccines. Both pathways lead to a PDUFA goal date, but they follow different statutory and regulatory frameworks under the FD&C Act and the Public Health Service Act respectively.

How can I build a career following FDA decisions like these?

Following FDA regulatory decisions professionally typically starts with structured training in the FDA framework, NDA/BLA processes and expedited pathways. The Entry to Regulatory United States Regulatory Affairs Course is designed to build these specific skills, alongside real work experience and job search support, making it a practical starting point for graduates, career changers and healthcare professionals moving into regulatory affairs.

Further Reading and Reference Sources

[Novel Drug Approvals for 2026 — U.S. Food and Drug Administration](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)

Published/updated: Ongoing, accessed August 2026

[Vaccines and Related Biological Products Advisory Committee, 18 June 2026 Meeting — U.S. Food and Drug Administration](https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-18-2026-meeting-announcement)

Published/updated: June 2026

[Garetosmab Biologics License Application Accepted for FDA Priority Review — Regeneron Pharmaceuticals](https://investor.regeneron.com/news-releases/news-release-details/garetosmab-biologics-license-application-accepted-fda-priority)

Published/updated: 2026

[Iberdomide NDA Acceptance Announcement — Bristol Myers Squibb](https://news.bms.com/news/corporate-financial/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Iberdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx)

Published/updated: 17 February 2026

[U.S. FDA Grants Priority Review of New Drug Application for Gilead's Bictegravir Plus Lenacapavir — Gilead Sciences](https://www.gilead.com/news/news-details/2026/u-s--fda-grants-priority-review-of-new-drug-application-for-gileads-once-daily-hiv-treatment-of-bictegravir-plus-lenacapavir)

Published/updated: 29 April 2026

[ITM Announces FDA Acceptance of NDA and PDUFA Date for 177Lu-Edotreotide (ITM-11) — ITM Isotope Technologies Munich SE](https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-announces-fda-acceptance-of-new-drug-application-nda-and-pdufa-date-for-n-c-a-177lu-edotreotide-itm-11-in-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-747/)

Published/updated: 2026

[Moderna's mRNA Flu Shot mFlusiva Snags FDA Nod After Refusal-to-File Imbroglio — Fierce Pharma](https://www.fiercepharma.com/pharma/modernas-mrna-flu-shot-mflusiva-snags-fda-nod-after-refusal-file-imbroglio)

Published/updated: August 2026

[FDA Accepts New Drug Application for Iberdomide as Treatment for RRMM — International Myeloma Foundation](https://www.myeloma.org/news-events/multiple-myeloma-news/fda-accepts-new-drug-application-iberdomide-rrmm)

Published/updated: 2026

[FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs — CancerNetwork](https://www.cancernetwork.com/view/fda-accepts-new-drug-application-for-177lu-edotreotide-in-gep-nets)

Published/updated: 2026

[Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare FOP — Regeneron Pharmaceuticals](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-phase-3-trial-adults-ultra-rare)

Published/updated: 2026

DISCLAIMER

This article is provided for informational purposes only. Regulatory guidance, legislative instruments and health authority policies evolve frequently. Always consult the most current official publications from the relevant health authority and seek qualified professional regulatory advice for specific product development, submission or compliance decisions. Entry to Regulatory training courses are designed for educational and career development purposes.

Speak to us today and find out how we can help you get into Regulatory Affairs. 

About the Author: Rabiea is an Honorary Associate Professor at UCL, former MHRA Health Authority reviewer, and CEO of Entry to Regulatory and Advanced Regulatory Consulting. After transitioning from retail pharmacy to regulatory affairs, she has dedicated her career to helping others make the same successful career change. Connect with her on LinkedIn for the latest regulatory affairs insights and career advice.